Search This Blog

Sunday, February 3, 2019

Revising Stark Self-Referral Law Raises Many Questions

If the  hospital you work for gives you a cybersecurity system, is that a violation of federal law? The Department of Health and Human Services (HHS) is thinking hard about that as it attempts to revise the Stark self-referral law, an HHS official said here Wednesday.
In June, HHS requested comments on how to revise the 1989 law, which “prohibits a physician from making referrals for certain designated health services payable by Medicare to an entity with which he or she (or an immediate family member) has a financial relationship (ownership, investment, or compensation), unless an exception applies,” as CMS notes on its website. One big concern was whether and how the laws were stifling efforts of practices to move from getting paid under a fee-for-service system to getting paid under a value-based system.
“We received 375 comments totaling about 3,500 pages,” Kimberly Brandt, CMS’s principal deputy administrator for operations, said Wednesday at an event sponsored by the Brookings Institution, a left-leaning think tank here. “The comments we got were extremely thoughtful and really gave us great insight into where it is people were having impediments to value-based care.”
Brandt listed several areas that the comments fell into. “The first area we heard about was alternative [payment] models and care coordination,” she said. “People were asking, ‘Should there be specific exceptions’ [for those arrangements] and how would those exceptions work? There was a lot about how that plays out and what should stay and what should go.”
Another area — one Brandt said CMS hadn’t really thought much about — “was in the area of being able to donate cybersecurity technology … How [does that] work in a system where a hospital asks a physician office to put a certain type of cybersecurity software in place; are they allowed to give that to them, or not? There were also a lot of questions about electronic health records and that kind of technology, particularly in coordinated care types of settings.”
Other issues included making sure any new exceptions would not exacerbate ability to have overutilization in the program, and issues of cash versus “in kind” gifts. “Is it OK if we provide pizza to the attending doctor who got caught because it’s -60° outside and he couldn’t get home?” she said.
image
(l-r) Tim Gronniger, Caravan Health; Bobbie Gostout, MD, Mayo Clinic; Kimberly Brandt, JD, Centers for Medicare & Medicaid Services; Kevin McAnaney, JD; Christen Linke Young, JD, Brookings Institution (Livestream photo courtesy Brookings Institution)
Overall, “the number one thing we heard about is clarity — commenters were very clear they wanted clarity in the definitions of ‘reasonableness’ and ‘fair market value,'” Brandt said. “Traditionally, those definitions have consistently been less than clear and have caused constructive debate in the industry, and people felt that without clarity, it held them back from being able to know where the line is.”
HHS deputy secretary Eric Hargan pointed out that his agency needs to be mindful of the consequences of changing the Stark law. “Most commentators believe that regulatory changes are needed to support the move [to] value-based payment, but they also recognize there is potential for program integrity vulnerability,” he said. “We cannot ignore the current fee-for-service system, and the reality is that it will be around in some form or fashion for the foreseeable future. It is the majority of the system right now, but it has a smaller and smaller percentage, yearly, of the overall market.” Rulemaking on the Stark law will begin “soon,” he added.
The department also is working on changes to the federal anti-kickback statute, which “prohibits the knowing and willful payment of ‘remuneration’ to induce or reward patient referrals or the generation of business involving any item or service payable by the Federal health care programs (e.g., drugs, supplies, or health care services for Medicare or Medicaid patients),” according to the HHS Inspector General’s website.
“Here too, we’re going to be very attentive to the need for program integrity,” said Hargan. “The questions include, ‘How can we expect a provider to improve outcomes for, say a patients with a poor track record of not showing up to appointments if we’re not willing to look at how a patient can get assistance in transporting them to those appointments? How can we encourage patients to take more ownership of their own healthcare without thinking about providing them — maybe free of charge — patient-empowering technologies such as a heart monitor or tablet? … I’m not prejudging these things; these are just questions that have been raised.”
The anti-kickback statute is a little more complicated to revise than the Stark law because it’s a criminal statute and is enforced by the Department of Justice, said Kevin McAnaney, a healthcare attorney here. Criminal prosecutors tend to be “risk averse” and would rather target too many people “than let a bad guy go … they have this world view that people are all out to rip us off.”
Under some of the new value-based payment systems like accountable care organizations (ACOs), providers are incentivized to keep patients within a certain referral network, “so it’s treading close to the line,” he said. In addition, some of the investments in an ACO, “even if you’re only [making them] for a commercial entity or in one of the waivered programs, those benefits also accrue to Medicare fee-for-service patients.”
The concern is that such arrangements could be targeted under the federal False Claims Act, where penalties “are three times the amount of the claim and a mandatory $15,000 per claim,” said McAnaney. “So if you’re looking at a value-based system … you’re talking a potentially huge number of claims, a huge number of referrals … So it really is a significant chill on a health system that’s trying to implement these programs.”

Nurses on their struggles with substance use disorder

Rates of substance use disorder have continued to grow in the U.S. and studies have shown that 10%-15% of health care professionals abuse substances at some point in their lifetime. Many individuals working in the health care field are dealing with patients, so these numbers present serious safety issues for their patients if a professional is impaired. To get some first hand insight on this issue, I have asked two nurses in recovery, Kristin L., RN, and Cynthie K., RN, to share their experience and knowledge on the subject to shed awareness on this issue.
Kristin has been sober for 13 years and began abusing prescription opioids during her career in nursing. She has been able to retain her license despite facing legal consequences. Cynthie has been sober for 6 months and is still facing consequences from her drug and alcohol abuse.
How did your addiction affect your career?
Kristin was working with intubated patients where they administered Fentanyl and she began stealing any extra Fentanyl because, as she explained, after she took it once, she had to have it every time she went to work. After 9 months she was caught and arrested the first time, resulting in the loss of her medical license. Kristin felt like she dodged a bullet by ending up with misdemeanors, but she began working as a medical secretary where she immediately started calling in prescriptions for herself. When she was caught doing this, she spent 4 months in jail and is now carrying the weight as a convicted felon. Fortunately, she was able to retain her nursing license after a 5 year monitoring program.
When Cynthie made the decision to get sober, she was working as Director of Nursing. She explains that working while impaired affected her judgment and decision making. She wasn’t able to perform to the best of her ability and no longer had the enthusiasm about work that she once had. She frequently called out of work because drinking became more important. Since her judgment was off, she thinks it could have had an effect on patient outcome which was potentially dangerous for families who were in difficult situations. She notes that she lost her job due to a DUI, but was able to maintain her license through the help of a nurse who worked with a statewide program for professionals with substance use disorder.
What kind of programs and support were you offered?
Through the Professional Assistance Procedure (PAP) program in Wisconsin that Kristin participated in, she was given a restricted license so she could still work as a nurse. She had to do weekly random drug screens, attend counseling, 12 step meetings, and submit quarterly reports to the nursing board. If at any time she did not comply to these standards, her license may have been suspended again.
In New York, Cynthie was able to get help through the Statewide Peer Assistance for Nurses (SPAN) program. A nurse who worked with SPAN helped Cynthie go to detox and treatment, allowing her to get help before her license was revoked as a result of her DUI. In this program, individuals are subject to random drug screenings while being closely monitored by a supervisor so they may continue to practice while obtaining the help and support of professionals.
What would you add to these programs to make them more effective?
Kristin and Cynthie both feel strongly that anyone working with narcotics or controlled substances should be subject to random drug screens. Both women believe that if we tested more people in hospitals and clinics, the numbers of addicts silently suffering would be astonishing. Kristin estimates that many providers would lose about 10% of the workforce due to substance abuse problems. She suggests that a great addition to the programs offered to her would be a yearly training on how to report to the nursing board. With these ideas implemented, the hope is for health care professionals to feel safe reporting anyone suffering in silence.
What measures can be taken for prevention of substance abuse in the health care field?
Despite different stories and consequences, both Kristin and Cynthie agree that more conversation about substance abuse, in both the health care field and within society as a whole, needs to take place. Both women explain it would be beneficial to invite a recovering health care professional, who has personally suffered through addiction, to share their story with others at yearly conferences or trainings. Kristin explained that having a person share their experience, as a health care professional suffering from addiction, can potentially help reduce the stigmas surrounding addiction. Kristin also believes this could help not only the individual struggling, but their families as well. Bringing awareness to the disease of addiction can help reduce the stigmas of addiction and open the lines of communication for other nurses in similar situations, in hopes of allowing them to reach out and ask for help.

Why the Fed Made a U-Turn : Perceived Risks to Growth Shifted

The Federal Reserve reversed course earlier this past week when it put interest rate rises on hold, prompted by rising risks to U.S. growth in the months ahead, rather than any signs the economy’s health is faltering now.
Fed Chairman Jerome Powell signaled on Wednesday the central bank will move to the sidelines to see whether the threats — including from the slowing global economy, trade tensions and the effect of the Fed’s rate increases over the last two years — generate a sharper-than-anticipated slowdown for a U.S. economy that continues to look solid by most measures.
The Fed’s new stance marked a U-turn from six weeks earlier when it raised rates and penciled in two increases in 2019.
To understand what happened, consider the two risks officials have confronted over the past year.
One is the risk that inflation accelerates as economic slack disappears, forcing the Fed to raise rates rapidly. This framework is embodied by the Phillips curve, which holds that tighter labor markets will drive stronger wage growth and faster price increases. While this relationship has broken down in recent decades, it strongly animates thinking inside the Fed.
The second risk is that a world of slower growth and an excess of savings over investment means the economy can’t tolerate interest rates as high as they used to be. This is sometimes called “secular stagnation.” It is one reason Japan’s aborted efforts to raise interest rates in the 1990s and early 2000s kept throwing its economy into recession.
After many years of historically slow U.S. growth, the economy accelerated last year. Fed officials began worrying more about the inflation risk, which under the Phillips curve framework called for lifting rates to pre-empt those price pressures. For more than a year, the unemployment rate has been at or below the bottom of a range — from 4% to 4.6% — that Fed officials estimate is consistent with stable inflation.
In addition, tax cuts and federal spending increases last year provided new economic stimulus. A similar episode during a low-unemployment spell in the late 1960s led to high inflation.
But this time, inflation hasn’t taken off, and has instead stayed just below the Fed’s 2% target. With the economy facing new headwinds, Mr. Powell said Wednesday the inflation risks had diminished — and with it, the need for additional, pre-emptive rate rises.
“They have shifted to being more worried about secular stagnation than they are about the risk of late-’60s inflation,” said Lewis Alexander, chief U.S. economist at Nomura Securities.
While global growth had shown signs of stumbling last year, data for Europe and China turned worse last fall. One problem for the Fed is that its main macroeconomic model doesn’t neatly account for global economic and financial linkages that began buffeting markets last year, said Andrew Levin, a former Fed adviser who now teaches at Dartmouth College.
“You’re in an environment where U.S. rates seem low but they’re actually high” compared to other rich economies, said St. Louis Fed President James Bullard in an interview.
Meanwhile, the Fed’s moves to raise rates had started to bite. Steven Blitz, chief U.S. economist at TS Lombard, traces the market’s recent swoon and the ensuing Fed pivot to late September, when the central bank pushed interest rates above the inflation rate for the first time in a decade.
For investors, higher rates meant something they hadn’t seen in a while: the ability to earn money holding cash. The return of cash as a viable asset class contributed to the repricing that has taken hold across other investment classes, said Mr. Blitz.
Mr. Blitz said Mr. Powell’s background colors his perspective. Mr. Powell isn’t trained as an economist and spent part much of his career in finance. “He is a credit-markets guy and is reacting to this market swoon sooner than his predecessors would have to keep this expansion going,” said Mr. Blitz. “He has to battle the Fed-model view that money is still cheap to say, ‘No, actually, it’s not.'”
Officials in early December had begun thinking about slowing their rate increases in 2019 and how to communicate this shift publicly.
They raised rates at their Dec. 18-19 meeting and sought to signal this milder policy path, said Mr. Bullard.
Their projections charted a shallower path of future rate increases. Mr. Powell tried to signal greater uncertainty about that path at his press conference. And the Fed’s policy statement watered down its language signaling future rate increases.
“All of that was not enough,” said Mr. Bullard.
Markets were already nervous about slowing global growth, trade tensions and the Fed’s rate plans before the December meeting. Investors turned even gloomier when Mr. Powell sounded more committed to tighter policy than many thought was warranted by the gathering growth risks.
Market volatility in the following days fueled a sudden rise in borrowing costs for businesses and households and falling stock prices. Short-term bond yields began rising above longer-dated yields, a so-called inversion of the yield curve that often precedes recessions by a year or two.
Inverted yield curves can steer lenders away from long-term loans to more-profitable short-term debt, constraining the availability of credit.
These tighter financial conditions shifted the way Fed officials perceived the risks to their forecast, particularly because it looked like poor communication about their intentions might be responsible for the narrowing in bond-yield spreads.
Financial markets settled down on Jan. 4 after Mr. Powell signaled more strongly that rate increases would be on hold.
Fed officials are calculating the combined effects of tighter financial conditions and a slowdown in foreign economies could keep a lid on domestic inflation, even if U.S. economic growth remains solid this year.
“Inflation is not running away from us,” said Dallas Fed President Robert Kaplan in an interview Friday. “My base case for the next couple of quarters would be that we take no action.”

Junk bonds are back

Junk-rated bonds and loans are flying off the shelves again, easing recent worries that a credit-market freeze could harm the economy.
Since Jan. 10, companies with below-investment-grade ratings, including TransDigm Group Inc. and Dun & Bradstreet Corp., have sold around $50 billion of bonds and loans, breaking a dry spell that saw just $29 billion of speculative-grade debt sold in November and December, according to LCD, a unit of S&P Global Market Intelligence.
After hunkering down during the difficult final months of 2018, investors in January found themselves with ample amounts of cash to buy new bonds. In many cases, they have been lured by enticing offers from companies considered relatively creditworthy in the pantheon of junk debt.
Like other risky assets such stocks, junk-bond prices largely have moved in response to the shifting messages of Federal Reserve officials, potentially leaving the market vulnerable if there is another turn by the central bank.
Bond prices fell sharply in early October when Fed Chairman Jerome Powell suggested the Fed had a way to go before it was done raising interest rates. They then rebounded when Mr. Powell reversed course in early January and sent strong signals that the central bank was potentially finished with rate increases for the foreseeable future.
Mr. Powell’s remarks on Jan. 4 “laid to rest the concern that the Fed could make a policy error,” giving investors the green light to start taking risks again, said David Norris, head of U.S. credit at TwentyFour Asset Management.
The amount of junk-rated debt issuance at any time matters for the U.S. economy. While robust sales can saddle companies with unsustainable debt loads and pave the way for subsequent pullbacks, they generally contribute to economic growth by enabling companies to refinance debt and invest in people and equipment. A sharp slowdown in debt sales, as occurred in late November and December, can quickly translate to slower economic growth.
For Fed officials, the fickle nature of debt investors presents challenges. If rates stay low for too long, financial bubbles can form. If the Fed adopts a tougher stance, the risk of a recession is heightened.
While the appetite for junk-rated debt has rebounded in January, there are signs it hasn’t yet returned to the exuberance exhibited before October. Then, concerns were growing about escalating corporate leverage levels and deteriorating investor protections in new debt sales.
As companies sold a hefty amount of debt in recent weeks, they have been forced in several cases to lean on one particular kind of debt — secured bonds — which is garnering more investor interest than secured loans and unsecured bonds.
When TransDigm sought financing last week for its $4 billion purchase of rival aerospace-parts maker Esterline Technologies Corp., it initially sold $3.8 billion of first-lien secured bonds, a record sale for this type of debt, according to LCD. Meanwhile, it dropped a planned $1 billion sale of unsecured notes. Two days later, the company returned to the market to sell another $200 million of secured notes while also issuing $550 million of unsecured bonds.
Similarly, data and analytics company Dun & Bradstreet on Friday sold nearly $4 billion of bonds and loans to fund its leveraged buyout by a group of private-equity companies. But that was only after shifting $100 million each from loan and unsecured bond tranches to secured bonds. It also made several investor-friendly changes to its package of protections, or covenants, placing stricter limits on its ability to issue more debt or pay its owners dividends.
Secured bonds are in a sweet spot because the appeal of loans, which carry floating-rate coupons that fluctuate with short-term rates set by the Fed, has diminished as it appears the Fed is now on hold. Unsecured bonds, whose holders typically are the first among debt investors to take losses in a bankruptcy, have also lost some of their luster amid continued concerns that the U.S. economy is due for a downturn, investors say.
Mr. Powell, at a press conference Wednesday, said officials were paying close attention to financial conditions, including interest rates and yield premiums, “because they have important macroeconomic implications.” Despite easing in recent weeks, he said financial conditions remain “significantly tighter” than they were previously.
At the moment, “the market is very open to good deals,” said Marc Bushallow, managing director of fixed income at Manning & Napier.
Still, Mr. Bushallow said his team didn’t spend much time looking at Dun & Bradstreet’s bond sale because “at this point in the cycle, we’re not buying a highly levered LBO.”

Small Businesses Are Waving the Caution Flag

An Alabama welding supply company is delaying purchases of new gas cylinders. A men’s clothing store in Louisiana has trimmed fall orders for suits and high-end sportswear. An information technology consulting firm in California is holding back on planned hiring.
After a banner year, many small businesses are becoming more cautious about their investment and hiring plans. Some are responding to early signs of slowing sales, while others fear that tariffs, unstable financial markets, the aftereffects of the government shutdown and other headwinds could damp economic growth in 2019.
Economic confidence among small firms, which edged downward for much of 2018, in January reached its lowest level since President Trump’s election, according to a monthly survey of 765 small firms for The Wall Street Journal by Vistage Worldwide Inc. Just 14% of firms expect the economy to improve this year, while 36% expect it to get worse.
For the first time since the 2016 election, small firms were more pessimistic about their own financial prospects than they were a year earlier, including plans for hiring and investment, according to the survey, which was completed shortly before the 35-day federal shutdown ended.
“We could be at a turning point,” said Richard Curtin, a University of Michigan economist who analyzed the data. “Recessions are not made of one firm collapsing, but of many firms cutting back in marginal ways.”
The Labor Department on Friday said nonfarm payrolls rose by a healthy 304,000 in January, indicating that hiring in the broader economy continues apace despite the headwinds to growth.
Nearly one in four small firms surveyed by Vistage said the Trump administration had hurt the outlook for their business.
At Atlas Welding Supply Co. Inc. in Tuscaloosa, Ala., sales in 2018 grew at a 30% clip before flattening out in November and December. “People were inquiring a lot, but they didn’t pull the trigger, not nearly at the rate we saw a year earlier,” said Bill Visintainer, chief executive of the 28-person industrial gas and welding supply company. In the past 90 days, customers began taking longer to pay their bills, he said.
In response, Mr. Visintainer is being more cautious about his company’s spending. For example, he said he is delaying purchases of new high-pressure cylinders used to deliver gas until customers place orders, instead of steadily adding to his stock in anticipation of strong demand. “I hate to lower my expectations,” said Mr. Visintainer, who fears political turmoil and potential interest-rate hikes are making his customers nervous, increasing the chances the economy slides into a recession.
Many small firms remain confident. Southwest Geotechnical LLC, a 35-person engineering consulting firm in Las Vegas, plans to add about a dozen employees this year after hiring more than that in 2018. The firm, which serves mainly residential and commercial builders, also will spend about $150,000 on lab-testing equipment for the new hires.
“Business is rocking,” said company owner Justin Stratton. “I am being told by developers that they are looking for a banner year.”
Overall, 66% of small firms expect revenue to grow this year, according to the Vistage survey, down from 83% in January 2018.
In parts of the country, real-estate markets seem less robust. Latitude 38 Housing Services, which provides housing to students, technology workers and others seeking co-living spaces in the San Francisco area, is looking to pay down several million dollars of debt. It may sell one building to raise cash and is being more cautious about acquisitions and renovations.
“We definitely feel the market has peaked,” said Tony Brettkelly, chief executive of the 18-person company.
Some entrepreneurs say they are struggling to decipher the economic tea leaves. Kenny Rubenstein, the third-generation owner of Rubensteins, a 95-year-old New Orleans haberdashery, said sales of suits and sportswear were strong last year. But when Mr. Rubenstein recently placed his fall 2019 orders, he purchased just 75% of what internal reports suggested he buy.
“I’d rather play it safe at this point,” said Mr. Rubenstein, who has about 20 employees. “I’m divided right down the middle,” he added “Half of me is very positive. Half of me is very nervous.”
Alvarez Technology Group, Inc., an information technology consultant in Salinas, Calif., said its agribusiness customers have cut back on orders for software and hardware in response to tariffs and other economic uncertainties.
“The pipeline we have for projects and the pipeline we have for new clients willing to spend money with us, both of those have slowed,” said Luis Alvarez, the company’s chief executive. “We were projecting 15% to 20% year-over-year growth. We are not seeing that yet,” particularly in the agribusiness sector, he said. “Clients are not so much pessimistic as they are being cautious.”
The 38-person firm has delayed plans to add five new employees. It also has become more cautious about spending and made sure it has credit lines in place.
Gold Systems Inc., a government contractor in Salt Lake City that gets half its revenue from the Environmental Protection Agency and other federal agencies, expects to feel the aftereffects of the government shutdown through most of 2019, Chief Executive Dave Wilcox said.
The company has begun to receive payments on invoices that piled up during the shutdown, but even if Congress averts a second shutdown, Mr. Wilcox said, Gold Systems will “continue to be conservative in everything we do just knowing there may be some lasting impacts.”
Some business owners are looking to grow despite their concerns. Webfoot Painting Co., a carpentry and painting business in Bend, Ore., with 55 year-round employees, is expanding into Portland even though labor costs have increased and sales leads were down 5% in January.
To play it safe, Webfoot’s co-founders, Travis Ulrich and Gavin Hepp, didn’t take any quarterly distributions or annual bonuses for 2018. The company has stepped up marketing but is shopping for less costly software, and has done away with monthly crew and office team lunches, a $2,000 expense, Mr. Ulrich said.
“It’s batten down the hatches; hold on to your cash,” he said. “We are scared, but we are not playing scared. We are playing super-conservative with our cash.”

China unveils tax cuts for graduates, low-income workers in stimulus drive

China will introduce tax breaks for small businesses run by recent graduates and low-income workers, according to a joint ministry announcement, as the country looks to boost spending and offset an economic slowdown.

Earlier this month China’s state planner said it would prioritise graduates and migrant workers in efforts to combat unemployment, which rose in the December quarter amid shrinking factory orders and lower consumer spending.
The cuts will target university graduates, self-employed people and those who have been unemployed for more than six months, said the Ministry of Finance, State Administration of Taxation and other departments in a joint statement released on Saturday.
People who are eligible for the scheme can deduct a total of 12,000 yuan ($1,779.73) from the taxes of their household over three years. The cuts take effect from January 1 and run until the end of 2021.
Companies who hire people designated as “needy” will also qualify for a tax deduction of 6,000 yuan per person per year for three years.
China has said it will introduce new stimulus measures this year after the Sino-U.S. trade war took a heavy toll on the economy in 2018.
The Finance Ministry this month said it will implement larger tax and fee cuts, targeting small firms and manufacturers, while the county’s state planner has unveiled incentives to boost retail spending.

Biotech week ahead, Feb 4

The earnings season hasn’t panned out well for pharma companies, with Amgen, Inc. AMGN 0.02%Novartis AG NVS 0.16% and Illumina, Inc. ILMN 1.08% reporting either disappointing results or a bleak guidance.
Even as the earnings news flow picks up pace, here are a few catalysts a biotech investor should focus on in the unfolding week.

Conferences

  • 15th Annual WORLDSymposium – Feb. 4–8, in Orlando, Florida
  • 12th annual Congress of the European Association For Hemophilia and Allied Disorders (EAHAD) – Feb. 6-8, in Prague, Czech Republic

Clinical Trial Results

Sienna Biopharmaceuticals Inc SNNA 4.85% is due to release Phase 3 data for SNA-001, its investigational therapy used for the reduction of light-pigmented hair in early February.
Avrobio Inc AVRO 7.95% is scheduled to release an update on Phase 1 study and two-year data for first patient treated with Fabry disease candidate AVR-RD-01 at the WORLDSymposium Wednesday, Feb. 6.
Protalix Biotherapeutics Inc PLX 13.85% will release Phase 3 pharmacokinetic data for Pegunigalsidase alfa, its Fabry disease treatment candidate, at the WORLDSymposium Thursday, Feb. 7
Sangamo Therapeutics Inc SGMO 6.67% is set to release Phase 1/2 preliminary safety and biochemical measurements for SB-318, its treatment candidate for MPS Type 1, at the WORLDSymposium Thursday, Feb. 7. The company will also release biochemical and safety data for SB-913, its MPS Type 2 treatment candidate, at the symposium the same day.
Catalyst Biosciences Inc CBIO 4.78% is due to present Phase 2 data for its hemophilia treatment candidate Marzeptacog alfa at the EAHAD annual Congress to be held between Feb. 6 and Feb. 8.

Earnings

Monday, Feb. 4
  • Alexion Pharmaceuticals, Inc. ALXN 2.7% (before the market open)
  • Gilead Sciences, Inc. GILD 0.07% (after the market close)
Tuesday, Feb. 5
Wednesday, Feb. 6
  • Boston Scientific Corporation BSX 0.52% (before the market open)
  • Regeneron Pharmaceuticals Inc REGN 0.24% (before the market open)
  • Enanta Pharmaceuticals Inc ENTA 3.1% (after the close)
Thursday, Feb. 7
  • Arrowhead Pharmaceuticals Inc ARWR 1.2% (after the close)
  • Twist Bioscience Corp TWST 0.56% (after the close)
  • Organovo Holdings Inc ONVO 0.99% (after the close)
  • Seattle Genetics, Inc. SGEN 0.77% (after the close)
  • Ligand Pharmaceuticals Inc. LGND 1.89% (after the close)
Friday. Feb. 8
  • ImmunoGen, Inc. IMGN (before the market open)

IPO

California-based clinical-stage biotech Alector, which develops treatments for neurodegeneration, is set to offer 9.25 million shares in an IPO, to be priced between $18 and $20. The company intends to list the shares on the Nasdaq under the ticker symbol ALEC.
Harpoon Therapeutics, an immuno-oncology company, plans to offer 5.4 million shares in an IPO, with the shares to be priced in the $13-$15 range. The shares will be listed om the Nasdaq under the ticker symbol HARP.
Gossamer Bio is planning to offer 14.38 million shares in an IPO. The company that develops therapeutics for immunology, cancer and inflammation is likely to price the shares at $16. The shares will be listed om the Nasdaq under the ticker symbol GOSS.